Adaptive design of confirmatory trials: Advances and challenges

Contemporary Clinical Trials

Volumn 45, Issue , 2015, Pages 93-102

  Lai, Tze Leung ^a   Lavori, Philip W ^a   Tsang, Ka Wai ^b  

^a STANFORD UNIVERSITY   (United States)

^b Stanford University   (United States)

Author keywords

Adaptive design; Adaptive randomization; Bayesian inference; Early stopping; Hybrid resampling; Multi arm bandits

Indexed keywords

ARTICLE; BAYES THEOREM; CONFIRMATION BIAS; STATISTICAL ANALYSIS; STATISTICAL MODEL; STUDY DESIGN; SURVIVAL; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HUMAN; METHODOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; SAMPLE SIZE; STANDARDS; UNITED STATES;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; RESEARCH DESIGN; SAMPLE SIZE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84955341791     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.06.007     Document Type: Article

References (72)

1. Bauer P. Multistage testing with adaptive designs (with discussion). Biomed. Inform. Med. Biol. 1989, 20:130-148.
2. Wittes J., Brittain E. The role of internal pilots in increasing the efficiency of clinical trials. Stat. Med. 1990, 9:65-72.
3. Stein C. A two-sample test for a linear hypothesis whose power is independent of the variance. Ann. Math. Stat. 1945, 16:243-258.
4. Gould A.L., Shih W.J. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm. Stat. Ser. A 1992, 21:2833-2853.
5. Herson J., Wittes J. The use of interim analysis in sample size adjustment. Drug Inf. J. 1993, 27:753-760.
6. Birkett M., Day S. Internal pilot studies for estimating sample size. Stat. Med. 1994, 13:2455-2463.
7. Denne J.S., Jennison C. A group sequential t-test with updating of sample size. Biometrika 2000, 87:125-134.
8. Fisher L. Self-designing clinical trials. Stat. Med. 1998, 17:1551-1562.
9. Denne S. Sample size recalculation using conditional power. Stat. Med. 2001, 20:2645-2660.
10. Jennison C., Turnbull B.W. Mid-course sample size modification in clinical trials based on the observed treatment effect. Stat. Med. 2003, 22:971-993.
11. Tsiatis A.A., Mehta C. On the efficiency of the adaptive design for monitoring clinical trials. Biometrika 2003, 90:367-378.
12. Proschan M., Hunsberger S. Designed extension studies based on conditional power. Biometrics 1995, 51:1315-1324.
13. Bauer P., Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994, 50:1029-1041.
14. Posch M., Bauer P. Adaptive two stage designs and the conditional error function. Biom. J. 1999, 41:689-696.
15. Jennison C., Turnbull B.W. Adaptive and nonadaptive group sequential tests. Biometrika 2006, 93:1-21.
16. Jennison C., Turnbull B.W. Efficient group sequential designs when there are several effect sizes under consideration. Stat. Med. 2006, 25:917-932.
17. Bartroff J., Lai T.L. Efficient adaptive designs with mid-course sample size adjustment in clinical trials. Stat. Med. 2008, 27:1593-1611.
18. Bartroff J., Lai T.L. Generalized likelihood ratio statistics and uncertainty adjustments in efficient adaptive design of clinical trials. Seq. Anal. 2008, 27:254-276.
19. Lorden G. Asymptotic efficiency of three-stage hypothesis tests. Ann. Stat. 1983, 11:129-140.
20. Bretz F., Schmidli H., König F., Racine A., Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom. J. 2006, 4:623-634.
21. Schmidli H., Bretz F., Racine A., Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biom. J. 2006, 4:635-643.
22. Simes R.J. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986, 73:751-754.
23. Stallard N., Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Stat. Med. 2003, 22:689-703.
24. Wang Y., Lan K.K.G., Ouyang S.P. A group sequential procedure for interim treatment selection. Stat. Biopharm. Res. 2011, 3:1-13.
25. Brannath W., Zuber E., Branson M., Bretz F., Gallo P., Posch M., Racine-Poon A. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat. Med. 2009, 28:1445-1463.
26. Jenkins M., Stone A., Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharm. Stat. 2011, 10:347-356.
27. Berry D.A. Bayesian clinical trials. Nat. Rev. Drug Discov. 2006, 5:27-36.
28. Berry S.M., Carlin B.P., Lee J.J., Müller P. Bayesian Adaptive Methods for Clinical 1069 Trials 2011, Chapman & Hall/CRC, Boca Raton FL.
29. Thompson W. On the likelihood that one unknown probability exceeds another in view of the evidence of two samples. Biometrika 1933, 25:285-294.
30. Meuer W.J., Lewis R.J., Berry D.A. Adaptive clinical trials: a partial remedy for the therapeutic misconception?. J. Am. Med. Assoc. 2012, 307:2377-2378.
31. Zhou X., Liu S., Kim E.S., Herbst R.S., Lee J.L. Bayesian adaptive design for targeted therapy development in lung cancer-a step toward personalized medicine. Clin. Trials 2008, 5:181-193.
32. Barker A.D., Sigman C.C., Kelloff G.J., Hylton N.M., Berry D.A., Esserman L.J. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 2009, 86:97-100.
33. Berry D.A., et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N. Engl. J. Med. 2009, 360:2055-2065.
34. Food and Drug Administration Center for Drug Evaluation and Re-search Guidelines for Industry: Adaptive Design Clinical Tri-als for Drugs and Biologics 2010, (http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf.).
35. Anon. Committee for medicinal products for human use reaction paper on methodological issues in confirmatory clinical trials planned with an adaptive design. Eur. Med. Agency 2007, CHMP/EWP/2459/02.. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf).
36. Gallo P., Anderson K., Chuang-Stein C., Dragalin V., Gaydos B., Krams M., Pinheiro J. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. J. Biopharm. Stat. 2010, 20:1115-1124.
37. Brannath W., Burger H.U., Glimm E., Stallard N., Vandemeulebroecke M., Wassmer G. Comments on the Draft Guidance on "Adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration. J. Biopharm. Stat. 2010, 20:1125-1131.
38. Chuang-Stein C., Beltangady M. FDA Draft Guidance on adaptive design clinical trials: Pfizer's perspective. J. Biopharm. Stat. 2010, 20:1143-1149.
39. Wittes J. Comments on the FDA Draft Guidance on adaptive designs. J. Biopharm. Stat. 2010, 20:1166-1170.
40. Liu Q., Chi Y.H. Understanding the FDA Guidance on adaptive designs: historical, legal, and statistical perspectives. J. Biopharm. Stat. 2010, 20:1178-1219.
41. Cook T., DeMets D.L. Review of draft FDA adaptive design guidance. J. Biopharm. Stat. 2010, 20:1132-1142.
42. Emerson S.S., Fleming T.R. Adaptive methods: telling "the rest of the story". J. Biopharm. Stat. 2010, 20:1150-1165.
43. Cheng B., Chow S.C. On flexibility of adaptive designs and criteria for choosing a good one-a discussion of FDA Draft Guidance. J. Biopharm. Stat. 2010, 20:1171-1177.
44. Wang S.J. Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues. J. Biopharm. Stat. 2010, 20:1090-1097.
45. Benda N., Brannath W., Bretz F., Burger H.U., Friede T., Maurer W., Wang S.U. Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion. J. Biopharm. Stat. 2010, 20:1098-1112.
46. Wang S.J. Editorial: adaptive designs: appealing in development of therapeutics, and where do controversies lie?. J. Biopharm. Stat. 2010, 20:1083-1087.
47. Chow S.-C. A note on special articles on adaptive clinical trial designs. J. Biopharm. Stat. 2010, 20:1088-1089.
48. Cox D.R. Commentary: the likelihood paradigm for statistical evidence by Richard Royall. The Nature of Scientific Evidence: Statistical, Philosophical, and Empirical Considerations 2004, 138-140. Univ Chicago Press. M.L. Tapper, S.R. Lele (Eds.).
49. Armitage P. Discussion of the paper by Jennison and Turnbull. J. R. Stat. Soc. Ser. B 1989, 51:334-335.
50. Goodwin G.C., Sin K.S. Adaptive Filtering, Prediction and Control 2009, Dover, Mineola NY.
51. Lai T.L., Ying Z. Recursive identification and adaptive prediction in linear stochastic systems. SIAM J. Control. Optim. 1991, 29:1061-1090.
52. Lai T.L., Zhu G. Adaptive prediction in nonlinear autoregressive models and control systems. Stat. Sin. 1991, 1:309-334.
53. Lai T.L., Robbins H. Asymptotically efficient adaptive allocation rules. Adv. Appl. Math. 1985, 6:4-22.
54. Lai T.L. Adaptive treatment allocation and the multi-armed bandit problem. Ann. Stat. 1987, 15:1091-1114.
55. Lai T.L., Liao O.Y.-W., Kim D.W. Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research. Control. Clin. Trials 2013, 36:651-663.
56. Bartroff J., Lai T.L., Shih M.C. Sequential Experimentation in Clinical Trials: Design and Analysis 2013, Springer, New York.
57. Lai T.L. Information bounds, certainty equivalence and learning in asymptotically efficient adaptive control of time-invariant stochastic systems. Topics in Stochastic Systems: Modelling, Estimation and Adaptive Control 1991, 335-368. Springer, New York. L. Gerencśer, P.E. Caines (Eds.).
58. Lai T.L., Lavori P.W., Liao O.Y. Adaptive choice of patient subgroup for comparing two treatments. Control. Clin. Trials 2014, 39:191-200.
59. dela Peña V., Lai T.L., Shao Q.M. Self-normalized Process: Limit Theory and Statistical Applications 2009, Springer, New York.
60. Efron B. Bootstrap methods: another look at the jackknife. Ann. Stat. 1979, 7:1-26.
61. Efron B. Better bootstrap confidence intervals. J. Am. Stat. Assoc. 1987, 82:171-185.
62. Chuang C.S., Lai T.L. Hybrid resampling methods for confidence intervals (with discussion). Stat. Sin. 2000, 10:1-50.
63. Lai T.L., Li W. Confidence intervals in group sequential trials with random group sizes and applications to survival analysis. Biometrika 2006, 93:641-654.
64. Lai T.L., Shih M.C., Su Z. Tests and confidence intervals for secondary endpoints in sequential clinical trials. Biometrika 2009, 96:903-915.
65. Kim, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011, 1:44-53.
66. He P., Lai T.L., Zheng S. Design of clinical trials with failure-time endpoints and interim analyses: an update after 15years. Control. Clin. Trials 2015, 45:103-112. (this issue).
67. Berkhemer O.A., Fransen P.S., Beumer D., van den Berg L.A., Lingsma H.F., Yoo A.J., et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 2015, 372:11-20.
68. Campbell B.C., Mitchell P.J., Kleinig T.J., Dewey H.M., Churilov L., Yassi N., et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 2015, 372:1009-1018.
69. Goyal M., Demchuk A.M., Menon B.K., Eesa M., Rempel J.L., Thornton J., et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 2015, 372:1019-1030.
70. Food and Drug Administration. Innovative/stagnation: Challenge and opportunity in the critical path to new medical products. FDA report 2004. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
71. Berry D.A. Adaptive clinical trials: the promise and the caution. J. Clin. Oncol. 2011, 606-609.
72. Lai T.L., Liao O.Y.-W., Zhu R.G. Adaptation in clinical development plans and adaptive clinical trials. Stat. Its. Interf. 2012, 5:431-442.